Abstract: Elevated intraocular pressure (IOP) is a signifi cant risk factor for the development and progression of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure dependent factors, are key to our understanding of the pathophysiology of these neurodegenerative diseases, that target the retinal ganglion cell. As we try to expand therapy beyond IOP control, medications are being assessed for their neuroprotective abilities. Brimonidine is an effective ocular hypotensive treatment both as a fi rst and second line agent, in the management of glaucoma and ocular hypertension. Brimonidine tartrate 0.2% is generally safe and well tolerated, with its safety profi le further enhanced in the altered formulation brimonidine-Purite ™ 0.1%. Beyond brimonidine's pressure lowering capacity, laboratory and early clinical evidence supports its neuroprotective potential. We await validation of this in human clinical trials.
Introduction
Glaucomatous optic neuropathy (GON) is the manifestation of a group of diseases that progressively destroy retinal ganglion cells and if undetected or untreated, cause visual fi eld loss and functional disability. With increasing prevalence in an ageing population, 1,2 identifi cation and treatment of patients to prevent visual disability have signifi cant implications for our communities.
As elevated intraocular pressure (IOP) is the most signifi cant risk factor for developing glaucomatous optic neuropathy, and for its progression, its reduction and control have been the mainstays of glaucoma management. However non-pressure-dependent factors also contribute to the pathophysiology of glaucoma. Glaucomatous damage develops in many individuals despite the existence of IOP readings consistently in the usual range (less than 21 mmHg), 2, 3 conversely in individual patients, despite IOP-reduction, there is continued progression of the GON. 4 With increased recognition of the neurodegenerative nature of glaucoma, antiglaucoma medications are being assessed for their ability to exert clinical benefi ts beyond IOP control, specifi cally their ability to protect retinal ganglion cells and to prevent neuronal cell death (neuroprotection). 5 Brimonidine tartrate 0.2% ophthalmic solution (Alphagan ® , Allergan) is a highly selective alpha-2 adrenergic agonist, which lowers IOP through increased uveoscleral outfl ow and decreased aqueous humour production. 6 Beyond this there has been interest in whether brimonidine has neuroprotective effects both in the laboratory and in clinical trials.
Pharmacology and mechanism of action of brimonidine
Brimonidine tartrate, a third generation alpha-2 adrenergic agonist, has more than 1000-fold selectivity for alpha-2 over alpha-1 receptors. 7 This gives it a distinct advantage over the fi rst and second generation clonidine and apraclonidine by reducing the risk of systemic side effects, such as systemic hypotension, bradycardia and sedation, as well as reducing the alpha-1 mediated ocular side effects seen more commonly with apraclonidine: conjunctival blanching, mydriasis and eyelid retraction. 7 On topical application, brimonidine readily penetrates the cornea and results in a reduction of the IOP within 1 hour. Peak effect is achieved within 2 to 3 hours and the trough drug effect occurs approximately 10 to 14 hours after instillation. 8 In most parts of the world, brimonidine is dosed twice daily and its rapid metabolism and short half-life help to reduce potential cardiovascular and respiratory side effects. 7 Brimonidine appears to lower IOP by a dual mechanism of action. Initial dosing causes a reduction in aqueous humour production whereas with chronic dosing, the predominant effect is an increase in uveoscleral outfl ow. 8 
Evidence for neuroprotection
Neuroprotection in glaucoma refers to the ability to preserve anatomic and functional integrity of the retinal ganglion cells other than by reduction of IOP, thus preserving the visual fi eld. 9 To evaluate the potential of a pharmacological agent to be useful clinically as a neuroprotectant in glaucoma, 4 criteria have been proposed. 10 1. There must be specifi c target receptors in the retina or optic nerve. 2. There must be laboratory evidence that supports it has a mechanism of action that enhances a neuron's resistance to injury. 3. It must be available at the retina or optic nerve at pharmacological concentrations required for a neuroprotective effect after topical dosing, and 4. It must have demonstrated neuroprotective activity in prospective randomized clinical trials. We will review current evidence that assesses brimonidine with respect to these criteria.
Laboratory evidence has demonstrated alpha-2 receptors in the retina. Immunohistochemical studies have shown the existence of alpha adrenergic receptors in human, bovine and porcine retina 11 , and in particular in the ganglion cell layer and inner nuclear layer of the rat retina. 10 Brimonidine requires a concentration of 2 nM to activate alpha-2 adrenergic receptors signifi cantly. 12 In a clinical study of 17 patients scheduled to undergo pars plana vitrectomy, topical brimonidine 0.2% was administered twice daily for 5 to 14 days prior to surgery. At the time of surgery an undiluted core of vitreous humour was obtained and brimonidine concentrations, determined. The cohort included phakic, aphakic and pseudo-phakic patients. The mean brimonidine concentration measured in the vitreous was 185 nM. As this is well above the 2 nM required for receptor activation, 13 it seems reasonable to assume that retinal levels are likely to be suffi cient to activate the alpha 2 receptors following topical instillation. Phakic eyes demonstrated a lower concentration than did pseudophakic or aphakic eyes, with phakic eyes achieving a mean concentration of 9.3 nM of brimonidine, as compared with 164 nM in aphakic eyes and 256 nM in pseudophakic eyes.
Studies of the effect of brimonidine on experimental animal models of optic nerve injury provide further evidence of its neuroprotective potential. In pre-clinical studies using the chronic ocular hypertensive rat model, the effect of retinal ganglion cell survival was assessed following subcutaneous administration of brimonidine, compared with timolol as the control. In brimonidine-treated eyes, retinal ganglion cell (RGC) death was reduced up to 50%, whereas with timolol, no neuroprotective effect was demonstrated.
14 Although both drugs have comparable IOP lowering effi cacy, neither drug lowered the IOP significantly when administered systemically, suggesting that the benefi cial effect seen, directly related to the neuroprotective effect. Further analysis of a rat model of glaucoma, where brimonidine was administered intraperitoneally, revealed attenuation of ganglion cell death independent of IOP reduction. 15 Retinal injury and brimonidine effects on this have been assessed with two rat models: induction of retinal ischemia and then reperfusion, as well as crush injury to the optic nerve. Administration of brimonidine enhanced retinal ganglion cell survival in both models. 16 In a similar rat model of retinal ischemia, Donello et al demonstrated preservation of the ERG b wave. 17 While the mechanism by which this neuroprotection is mediated is not completely understood, alpha-2 adrenergic receptor stimulation might inhibit signals that trigger the apoptotic cascade in the RGC. 18 Brimonidine appears to meet the fi rst 3 criteria required of a neuroprotectant; support of clinical trials is necessary to meet the fourth.
An initial randomized controlled study, comparing the effects of brimonidine and timolol on visual field loss, after acute primary angle closure crisis, found no difference in prevalence of visual field defects or rate of field progression between the brimonidine and timolol treated groups. 19 Brimonidine for glaucoma and OH Another randomized double-masked pilot study evaluated the neuroprotective effi cacy of brimonidine, when applied to eyes of patients undergoing laser treatment for extrafoveal and juxtafoveal choroidal neovascularization. 20 Twenty eyes were randomized to receive brimonidine 0.2% (study group, 11 eyes) or placebo (matched control group, 9 eyes). Brimonidine was instilled twice daily for 4 to 48 hours pre-laser treatment and was continued for one month post-laser. In each group, 2 eyes had severe visual loss from recurrence of the CNV but in the remainder, signifi cant improvement of visual acuity was noted in the study group but not in the control group. The authors proposed that brimonidine improved the visual outcome of laser treated CNV by protecting the neuroretina against laser-induced collateral damage.
More recently Tsai et al in a prospective unmasked study compared the effects of brimonidine 0.2% with timolol 0.5% on retinal nerve fi ber layer (RNFL) thickness in ocular hypertensive patients. Using scanning laser polarimetry (GDx) to measure the RNFL, they demonstrated quantitatively less progression of RNFL damage with brimonidine versus timolol 0.5% in these patients over 12 months. 21 In a prospective clinical trial, Gandolfi et al compared visual fi eld deterioration rates in patients randomized to either topical brimonidine or to 360° argon laser trabeculoplasty (ALT). After 18 months of follow up, despite brimonidine reducing IOP less than the ALT, it appeared to be more effective than the laser in reducing fi eld deterioration, in progressing glaucomatous eyes. 22 Contrast sensitivity has also been shown to improve in brimonidine treated eyes of newly diagnosed glaucoma patients. This effect was independent of IOP lowering effects, supporting a neuroprotective mechanism. 23 The Low-Pressure Glaucoma Treatment Study (LoGTS) is a large double-masked multi-center, randomized clinical trial comparing the visual outcomes of "low pressure glaucoma" patients randomized to receive either twice daily brimonidine tartrate 0.2% or timolol maleate 0.5%. One hundred and ninety patients were recruited between 1998 and 2000 and have been followed for at least 4 years. The main study outcome is visual fi eld stability. 24, 25 Results are expected shortly; they are hoped to advance understanding of these patients, where non-pressure dependent factors are more likely to be operative. 25 
Clinical effi cacy studies
Since its introduction in the Australasian market in October 1997, there has been strong growth in the use of brimonidine tartrate 0.2% both as a fi rst and second line treatment in patients with POAG and ocular hypertension. 26 The hypotensive effi cacy of brimonidine as monotherapy in glaucoma and ocular hypertension has been studied in a many clinical trials and compared with all other classes of topical hypotensive agents.
Initial clinical trials assessed effi cacy of brimonidine tartrate 0.2% compared with timolol maleate 0.5%. One year data in 2 clinical trials found that brimonidine produced similar mean decreases in the IOP at peak compared with timolol, but at trough, the hypotensive effect was less than with timolol. Overall brimonidine demonstrated sustained IOP lowering effi cacy comparable with timolol.
27,28,29 When followed for 3 or 4 years of continuous use, brimonidine maintained an IOP lowering effi cacy comparable with timolol and assessment of long term visual fi eld preservation in both groups, was essentially the same. 30, 31 Brimonidine has also been compared with betaxolol 0.25%, which because of its relative cardio-selective adrenergic antagonist activity, offers greater safety from pulmonary side effects, than the non-selective beta-blockers, such as timolol and because of its pharmacokinetics, is also less likely to precipitate cardiac side effects.
32‚33
Judging clinical success after 4 months (IOP reduction, quality of life effects and adverse effects), brimonidine 0.2% showed a greater clinical success than betaxolol. 34 A previous clinical trial reported similar results.
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A meta-analysis of 3 clinical studies comparing, the effi cacy and harm of latanoprost for IOP reduction in glaucoma patients, with brimonidine, found that there was no signifi cant reduction in the mean IOP at 3 months post treatment in the latanoprost group compared with the brimonidine group. Pooled data of adverse events between these two drugs found that patients in the brimonidine group had a signifi cant increase in the number of ocular adverse events (excluding hyperemia). 36 Three separate studies evaluated the effi cacy and safety of brimonidine compared with dorzolamide when used as monotherapy. While there was no overall difference in IOPlowering effi cacy, ocular stinging and burning were more common with dorzolamide. 37, 38, 39 Several randomized controlled studies have assessed effi cacy and safety of brimonidine as adjunctive therapy. When added to ongoing beta-blocker therapy, brimonidine was shown to reduce IOP signifi cantly. 40, 41 Similarly, when added to latanoprost, brimonidine demonstrated signifi cant additional IOP lowering capacity. 41, 42 Clinical trials assessing the effi cacy of a fi xed combination of brimonidine 0.2% and timolol 0.5% (contribution of elements studies) showed mean IOP reductions were greater with the fi xed combination (Combigan ® , Allergan) than when the individual agents each were used alone. 43 The advantage of the fi xed combination, ease and convenience of instillation, without drug dilution seen when 2 drops are instilled too close together in time, might result in better patient compliance, thus leading to the higher success rate with this treatment. 44 These effi cacy studies support the versatility of brimonidine as an effective ocular hypotensive agent in patients with glaucoma and ocular hypertension. It is effective as monotherapy and as an adjunctive agent, with the effect being maintained over time.
Safety and tolerability
Evaluating effi cacy and safety of brimonidine 0.2% after 1, 3 and 4 years of use, various studies have supported its overall safety and tolerability: no clinically signifi cant effects on mean heart rate, blood pressure or pulmonary function. 28, 29, 30 Unlike timolol, which can induce cardiovascular and pulmonary side effects, 45 brimonidine generally is not contraindicated in patients with cardiopulmonary disease.
These studies supported a favorable safety profi le for brimonidine. The most common systemic side effects included dry mouth, fatigue or drowsiness and headache. 28, 29, 30 and the most common ocular side effects seen included ocular irritation, follicular conjunctivitis and blurred vision.
After 1 and 4 years of use, comparative studies between timolol and brimonidine showed equivalent tolerability. There was a slightly greater frequency of burning and stinging from timolol, and of oral dryness and ocular allergies in the brimonidine group. 30 When brimonidine was compared with betaxolol suspension, both agents were equally well tolerated, 32, 35 although a higher degree of hyperemia has been reported with betaxolol in another clinical trial. 46 Brimonidine is more stable and less likely to produce an allergic reaction compared with apraclonidine. 47 However, the major obstacle to long-term use of brimonidine is its propensity to cause ocular allergic reactions, 27, 28 with reported incidence rates of follicular conjunctivitis of 12.7% (twice daily dosing) and 15.7% (thrice daily dosing) at 1 year. 27 For the third year of use, this rate was 4.2%. 48 In all cases of allergy, symptoms resolved following discontinuation.
Demographic and clinical factors associated with brimonidine-induced allergy showed that affected individuals had a higher frequency of ocular allergy to all eye drops and a reduction of tear fi lm production. 49 Allergan Inc., (Irvine, CA) released a reformulated solution of brimonidine, preserved with chlorine dioxide (Purite ™ ) rather than benzalkonium chloride (BAK), and reduced the concentration of brimonidine to 0.15%. BAK, the most common antimicrobial preservative used in topical ophthalmic preparations, has the potential to accumulate in ocular tissues, and to cause toxicity and/or adverse effects, particularly if there is chronic dosing with multiple glaucoma therapies. 50, 51 In contrast Purite (which is converted to natural tear components when exposed to sunlight) has a wide spectrum of antimicrobial activity and a very low level of toxicity. This formulation (brimonidine 0.15%-Purite), despite having 25% less active drug than brimonidine 0.2%, has comparable hypotensive effi cacy, as well as having 41% lower incidence of allergic conjunctivitis. 52, 53 Currently this formulation is only available through the special access scheme for patients in Australia.
Brimonidine is absolutely contra-indicated in children; because of a less mature blood:brain barrier, they are susceptible to potentially serious central nervous system side effects including sleepiness, lethargy, bradycardia, hypotension, apnea and coma. 54 
Patient perspectives, acceptability, satisfaction, implications of neuroprotection
Effectiveness of any medication in the treatment of glaucoma depends on patient adherence to and persistence with the therapeutic regimen. Factors that infl uence these patient factors include, absence of symptoms from their disease, the number of topical medications, dosing frequency and adverse effects associated with instillation, such as burning and stinging. 55, 56 Quality of life assessments, as scored on the Glaucoma Disability Index, of patients on brimonidine as monotherapy, showed no worsening in the quality of life during the study period. 34 Fixed combinations of brimonidine 0.2%/timolol 0.5% (Combigan ® ) have demonstrated signifi cantly lower rates of allergy of up to 50%, when compared with the individual components 43, 57 and greater tolerability, with less burning, when compared with dorzolamide/timolol combinations. 58 This benefi t may be attributable to the lower concentration of BAK that is present in Combigan ® compared with the individual components and with the fi xed combination of dorzolamide/timolol. 43 It has also been suggested that the topical beta blocker effects of timolol, may have a protective effect in reducing ocular allergy. 59, 60 Its vasoconstrictive effect and reduced conjunctival hyperemia may be the mechanism by which Combigan ® achieves better tolerance and reduced local side effects when applied to the eye. 43 When comparing quality of life measures and patient satisfaction between dosing with brimonidine 2% and brimonidine-Purite ™ 0.15%, patients reported superior satisfaction and comfort ratings with the latter formulation. 52 Overall brimonidine 0.2% demonstrates hypotensive effi cacy, and is tolerated by the majority of patients. Future availability of the Purite ™ formulation will reduce the frequency of topical allergy, without compromising IOP lowering effi cacy. Its twice daily dosing, availability in fi xed dose combinations, together with its adult safety profi le contributes to satisfaction, compliance and persistence with treatment If clinical evidence supports neuroprotective benefi ts, brimonidine might offer a new therapeutic paradigm, to preserve visual function, beyond IOP reduction.
Conclusions, place in therapy
Brimonidine tartrate 0.2%, a highly selective alpha-2 adrenergic agonist, is generally an effective and safe ocular hypotensive agent for the long term management of glaucoma and ocular hypertension, whether used as monotherapy, adjunctive therapy or replacement therapy in the treatment of glaucoma. Limiting the success of brimonidine 2% as a fi rst line agent, is its rate of topical allergy, but this is less common with the brimonidine-Purite ™ formulation. If clinical studies with brimonidine support laboratory evidence of a neuroprotective effect, our treatment paradigm will shift beyond IOP-reduction, and begin to focus on our ability to preserve visual function for patients, through both neuroprotection and ocular hypotension.
